
即时询价 ×
* 必填项
请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。
Inquiry Online
×
* Required Fields.
Please complete the form below and we will contact you shortly.
Bulk Inquiry
×
* Required Fields.
Please complete the form below and we will contact you shortly.

CAS号 | 1225497-78-8 | 货号 | BCP02852 |
中文名 | ON-01910 | ||
英文名 | ON-01910 | ||
中文别名 | |||
英文别名 | Rigosertib;ON01910;ON 01910; | ||
SMILES | |||
化学名称 | |||
分子式 | C21H24NNaO8S | 分子量 | 473.47 |
纯度 | 98% | 配送 | 惯例下常温包邮 |
产品描述 | Rigosertib is non-ATP-competitive inhibitor to PLK1 with IC50 of 9 nM. Rigosertib also exhibits inhibition against PLK2, PDGFR, Flt1, BCR-ABL, Fyn, Src, and CDK1, with IC50 of 18-260 nM. Rigosertib shows cell killing activity against 94 different tumor cell lines with IC50 of 50-250 nM, including BT27, MCF-7, DU145, PC3, U87, A549, H187, RF1, HCT15, SW480, and KB cells. While in normal cells, such as HFL, PrEC, HMEC, and HUVEC, Rigosertib has little or no effect unless its concentration is greater than 5-10 μM. In HeLa cells, Rigosertib (100-250 nM) induces spindle abnormalities and apoptosis. Rigosertib also inhibits several multidrug resistant tumor cell lines, including MES-SA, MES-SA/DX5a, CEM, and CEM/C2a, with IC50 of 50-100 nM. In DU145 cells, Rigosertib (0.25-5 μM) blocks cell cycle progression in G2/M phase, results in an accumulation of cells containing subG1 content of DNA, and activates apoptotic pathways. In A549 cells, Rigosertib (50 nM-0.5 μM) induces loss of viability a |
相关产品推荐
查看更多 >Tags:ON-01910 供应商,ON-01910 购买,ON-01910 生产,ON-01910 批量,ON-01910 供应,ON-01910 订购,ON-01910 采购